Check for updates

OPEN ACCESS

EDITED BY Qi Li, The First Affiliated Hospital of Chongqing Medical University, China

REVIEWED BY Serefnur Ozturk, Selcuk University, Türkiye Nandavar Shobha, Manipal Hospitals, India

*CORRESPONDENCE Tom J. Moullaali ⊠ tom.moullaali@ed.ac.uk

RECEIVED 16 August 2023 ACCEPTED 04 September 2023 PUBLISHED 28 September 2023

CITATION

Moullaali TJ, Walters R, Rodrigues M, Samarasekera N, Bernal J, Wang X, Humphreys C, Wardlaw JM, Farrall A, Smith C, Anderson CS, Al-Shahi Salman R and McKinstry B (2023) Association between systolic blood pressure variability and severity of cerebral amyloid angiopathy in incident intracerebral hemorrhage. *Front. Stroke* 2:1278610. doi: 10.3389/fstro.2023.1278610

COPYRIGHT

© 2023 Moullaali, Walters, Rodrigues, Samarasekera, Bernal, Wang, Humphreys, Wardlaw, Farrall, Smith, Anderson, Al-Shahi Salman and McKinstry. This is an open-access article distributed under the terms of the **Creative Commons Attribution License (CC BY)**. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Association between systolic blood pressure variability and severity of cerebral amyloid angiopathy in incident intracerebral hemorrhage

Tom J. Moullaali^{1,2*}, Rachel Walters¹, Mark Rodrigues¹, Neshika Samarasekera¹, Jose Bernal^{1,3}, Xia Wang², Catherine Humphreys⁴, Joanna M. Wardlaw¹, Andrew Farrall¹, Colin Smith¹, Craig S. Anderson^{2,5}, Rustam Al-Shahi Salman¹ and Brian McKinstry⁶

¹Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom, ²Faculty of Medicine, The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia, ³German Centre for Neurodegenerative Diseases (DZNE), Magdeburg, Germany, ⁴Department of Neuropathology, Edinburgh Royal Infirmary, Edinburgh, United Kingdom, ⁵Global Brain Health, The George Institute China, Beijing, China, ⁶Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom

Introduction: The role of systolic blood pressure (SBP) variability in the pathogenesis of cerebral amyloid angiopathy (CAA) as an underlying cause of intracerebral hemorrhage (ICH) is unknown. We studied SBP variability before ICH according to CAA severity at autopsy.

Methods: We collected office (primary care or hospital clinic) BP readings during 10 years before first-ever ICH onset in adults who died and had brain research autopsy in the Lothian IntraCerebral Hemorrhage, Pathology, Imaging, and Neurological Outcome (LINCHPIN), prospective, population-based, inception cohort study. A neuropathologist assessed CAA severity using a histopathological rating scale, masked to BP readings. Functional principal component analysis was used to model SBP levels by time before ICH, and logistic regression models assessed associations of SBP variability indices with CAA severity (moderate-severe vs. absent-mild) adjusted for age, gender, and mean SBP.

Results: Among 72 adults (median age 81 [interquartile range 76–86], 56% female, median number of SBP readings 11 [3–19]), patients with moderate-severe CAA had similar mean SBP (143 vs. 145 mmHg, P = 0.588) but lower SBP variability (SBP standard deviation [SD] 14 vs. 17 mmHg, P = 0.033) compared with patients with absent-mild CAA, and their SBP trajectories seemed to differ over 10 years before ICH. The odds of moderate-severe CAA were higher with lower maximum SBP (adjusted OR per 10 mmHg lower: 1.53, 95% confidence interval [CI] 1.09–2.15; P = 0.015) and lower SBP range (1.29 [1.03–1.61]; P = 0.028), but not SBP SD (1.95 [0.87–4.38]; P = 0.11).

Discussion: Compared with absent-mild autopsy-verified CAA, moderate-severe CAA is associated with lower maximum and range of pre-morbid SBP.

KEYWORDS

intracerebral hemorrhage, blood pressure variability, cerebral amyloid angiopathy, autopsy (research), cohort study

Introduction

Two cerebral small vessel disease (CSVD) subtypes are among the commonest causes of spontaneous intracerebral hemorrhage (ICH; Al-Shahi Salman et al., 2009): arteriolosclerosis (also known as age-related deep-perforating arteriopathy), which can occur anywhere in the brain, and cerebral amyloid angiopathy (CAA), which is confined to cortical and leptomeningeal vessels (Samarasekera et al., 2012).

High blood pressure (BP) is an important modifiable risk factor for CSVD-associated ICH (O'Donnell et al., 2016). The Perindopril Protection Against Recurrent Stroke Study (PROGRESS) showed that in patients with a history of stroke (including ICH), treatment with an angiotensin-converting-enzyme inhibitor with or without a diuretic lowered average systolic blood pressure (SBP) levels and reduced the risk of future CSVD-associated ICH by 50% compared with placebo (Weinberger, 2001). Notably, there was no apparent heterogeneity in the treatment effect according to the predicted underlying CSVD subtype underlying the ICH during follow-up (non-CAA vs. CAA using MRI criteria; Knudsen et al., 2001; Arima et al., 2010).

A population-based study of SBP levels before incident stroke reported differences in premorbid SBP levels according to ICH location, with lower mean and maximum SBP levels observed in people with lobar ICH location compared to people with deep or infratentorial ICH location (Fischer et al., 2014). Higher and more variable SBP (SBPV variability, SBPV) being associated with incident cardiovascular disease, stroke, and renal impairment (Stevens et al., 2016), and the severity and progression of CVSD rated on brain imaging (Ma et al., 2020; Tully et al., 2020). However, direct evidence about the role of high or variable SBP (SBP variability, SBPV) in the pathogenesis of CAA is limited (Banerjee et al., 2017).

We hypothesized that differences in SBP levels before ICH might exist according to underlying CVSD subtype, with CAArelated ICH being associated with lower and less variable SBP compared with non-CAA related ICH (i.e., arteriolosclerosisrelated ICH, driven by standard vascular risk factors including high and variable SBP). Therefore, we aimed to determine the association between long-term visit-to-visit SBPV in the preceding 10 years according to the severity of CAA verified at autopsy after ICH.

Materials and methods

Setting: lothian intracerebral hemorrhage, pathology, imaging, and neurological outcome study

The Lothian Audit of the Treatment of Cerebral Hemorrhage (LATCH) was a prospective population-based registry that identified all adults (age ≥ 16 years) with incident symptomatic stroke due to ICH whilst resident in the Lothian region of Scotland, UK, between 1 June 2010 and 31 May 2013, inclusive (Samarasekera et al., 2015a). The Lothian IntraCerebral Hemorrhage, Pathology, Imaging, and Neurological Outcome (LINCHPIN) study was a nested prospective community-based research study examining the

causes of ICH using research autopsy in the case of death. The design and methods of the LINCHPIN study are described in detail elsewhere (Samarasekera et al., 2015b).

In brief, patients with incident ICH ascertained by LATCH were invited to consent to research autopsy where a neuropathologist (CS) took 1 cm cubed brain tissue samples from all lobes of the brain, the cerebellum and brainstem for research purposes; the remainder of the brain was returned to the donor's body. For patients who lacked mental capacity, consent was sought from their nearest relative or a legal representative in accordance with the statutory requirements of the Human Tissue (Scotland) Act 2006. The Scotland A Research Ethics Committee approved the study (10/MRE00/23).

Participants

Patients with incident first-ever CSVD-associated ICH; a symptomatic event (new headache, neurological symptoms, or altered consciousness), referable to a discrete parenchymal bleed (confirmed by temporally consistent radiology or pathology findings). For the present analysis, patients were included if they participated in the LINCHPIN study and had research autopsy. We excluded cases of recurrent ICH, isolated extra-axial intracranial hemorrhage, and ICH definitely attributable to a macrovascular cause (e.g., arteriovenous or cavernous malformation, cerebral aneurysm, venous thrombosis), tumor, trauma, and hemorrhagic transformation of ischemic stroke.

We extracted baseline demographic and clinical characteristics of patients with incident first-ever ICH from the LATCH database, including age and sex, cardiovascular disease diagnoses and risk factors, medications prescribed at the time of ICH diagnosis (BPlowering, antiplatelet and anticoagulant medications), and baseline BP and Glasgow coma scale (GCS) score.

BP data collection

We collected up to six office (primary care or hospital clinic) BP readings per year during 10 years before the time of onset of ICH from paper and electronic healthcare records, and entered these data into the LATCH database according to standard operating procedures.

Patient-level long-term visit-to-visit SBP levels and SBPV

We calculated the following summary measures of patientlevel long-term visit-to-visit SBP levels and SBPV during 10 years before ICH onset for patients with available BP data: mean and standard deviation (SD, primary summary measure of SBPV); secondary measures of SBPV, including: maximum; minimum; range; coefficient of variation (CV) = SD/mean × 100; and residual standard deviation (RSD) = SD adjusted for change in SBP over time.

Pathological characteristics on research autopsy

We used pathological characteristics about patients enrolled in LINCHPIN who died during study follow-up and consented to autopsy examination by a neuropathologist (CS). A consensus histopathological rating scale was used for CAA, which was rated absent, mild, moderate-severe (Supplementary material).

Statistical analysis

We conducted analyses according to a pre-specified protocol. We present summary data by frequency (%) for categorical variables, and mean (SD) or median (interquartile range, IQR) for continuous variables. To identify potential confounders of the association between lower long-term visit-to-visit SBPV with severity of underlying CAA, we compared baseline demographic and clinical characteristics of the cohort after stratification by absent-mild vs. moderate-severe CAA on research autopsy. Next, we compared the summary measures of patient-level long-term visit-to-visit SBPV during 10 years before ICH by absent-mild vs. moderate-severe vs. CAA on research autopsy. We present all univariable comparisons using the Chi squared test for categorical data, and the Kruskal-Wallis rank test for continuous data. Finally, we assessed associations of summary measures of lower longterm visit-to-visit SBPV during 10 years before ICH per 10 mm Hg decrease (continuous variable) in logistic regression models adjusted for mean SBP and potential confounders identified in univariable analyses.

We used STATA version 16.1 (Stata Press, 2019) in all analyses. We used FPCA in MATLAB R2019a (The Mathworks Inc., 2019) to identify the average (mean) pattern of long-term visit-to-visit SBP levels during 10 years before ICH onset, stratified by absent-mild vs. moderate-severe vs. CAA on research autopsy. Functional principal component analysis (FPCA) can be applied to sparse longitudinal SBP data to provide a graphical representation of average patterns of SBP over time for illustrative purposes (Shen et al., 2017).

Results

There were 72 patients who participated in the LINCHPIN study and had research autopsy data available by 16 December 2019 (median age 81 [IQR 76–86], 56% female, median number of BP readings 11 [3–19]). Of these, 69 (96%) had BP data available during 10 years before ICH onset; 62 (86%) had \geq 2 BP readings required for calculation of the primary summary measure of long-term visit-to-visit SBPV (SD of SBP).

Table 1 shows the characteristics of patients with incident first-ever ICH, stratified by severity of CAA on research autopsy (absent-mild vs. moderate-severe). Compared with patients with absent-mild CAA, patients with moderate-severe CAA were more likely to have lobar ICH location and less likely to have deep or infratentorial ICH location (85 vs. 32% and 15 vs. 68%, p < 0.001, respectively), and have lower systolic and diastolic BP at presentation (163 vs. 179 mm Hg, p = 0.023 and; 84 vs. 96 mm Hg, p = 0.027, respectively). There were no other significant differences

in baseline demographic and clinical characteristics. Nor was there a statistically significant difference between median time from ICH to research autopsy. The numerical differences in time from ICH to autopsy (63 vs. 15 days for moderate-severe CAA vs. absent-mild CAA, respectively, p = 0.31) probably reflect the poorer prognosis from deep ICH amounting to earlier death and earlier autopsy on average, compared with lobar CAA-related ICH. These differences did not affect technical factors related to assessment of CAA severity at autopsy.

When SBP data were modeled using a functional data analysis method and stratified by absent-mild vs. moderate-severe CAA on research autopsy, there appeared to be qualitative differences in the patterns of long-term visit-to-visit SBP during 10 years before ICH onset (Figure 1). Compared with patients with absent-mild CAA, patients with moderate-severe CAA had similar mean SBP (143 [13] mmHg vs. 145 [SD 15] mmHg from a median of 8 vs. 11 BP readings; p = 0.59 and p = 0.25, respectively) but lower patient-level summary measures of long-term visit-to-visit SBPV (Table 2).

In binary logistic regressions model adjusted for age, sex and mean SBP, every 10 mmHg decrease in SD of SBP during 10 years before ICH onset was associated with a non-significant 95% increase in the odds of moderate-severe CAA (adjusted OR [95%CI]: 1.95 [0.87–4.38], p = 0.11; Table 3 model 2). Of the secondary summary measures of long-term visit-to-visit SBPV during 10 years before ICH onset, only lower maximum and range of SBP were significantly associated with moderate-severe CAA after adjustment for mean SBP (adjusted OR per 10 mm Hg decrease in the summary measure: 1.53 [1.09–2.15], p = 0.015 and; 1.29 [1.03–1.61], p = 0.028, respectively, Table 3 model 2).

Discussion

In this population-based cohort which included 72 patients with ICH who had research autopsy, several summary measures indicating lower long-term visit-to-visit SBPV before ICH (lower maximum and smaller range, but not SD of SBP), were associated with moderate-severe CAA, independently of age, sex, and mean SBP.

High BP has long been recognized as an important risk factor for non-lobar ICH (Brott et al., 1986), where the underlying pathology is principally arteriolosclerosis (non-CAA CSVD; Rodrigues et al., 2018), However, accumulating evidence indicates that high BP is also a risk factor for lobar ICH (Arima et al., 2010; Biffi et al., 2015), whereby non-CAA and CAA CSVD exist independently or co-exist, to varying degrees (Rodrigues et al., 2018). Yet, differences in premorbid BP control seemed to exist according to ICH location in a previous population-based study, with lower mean and maximum premorbid SBP levels observed in patients with lobar compared to deep or infratentorial ICH (Fischer et al., 2014). Our findings indicate these differences may be explained by the principal CSVD subtype underlying incident ICH.

Current models of non-CAA and CAA pathogenesis may provide a basis for this. In the brain, higher intracranial pulsatility and reduced cerebral vasoreactivity are manifestations of increased arterial stiffness, and these variables are among several that may contribute to the pathogenesis of non-CAA

	Cerebral amylo	P^					
	Absent-mild ($N = 38$) Moderate-severe ($N = 34$)						
Median time from ICH to autopsy, days	15 (7–519)	63 (9–628)	0.30				
Demographics							
Age at onset, years	82 (75–87)	81 (76–85)	0.76				
Sex, female	20 (53)	20 (59)	0.60				
Clinical characteristics at diagnosis							
Medical history							
Hypertension	27 (71)	18 (53)	0.11				
Atrial fibrillation	13 (34)	6 (18)	0.11				
Myocardial infarction	2 (5)	3 (9)	0.55				
Ischemic stroke	5 (13)	5 (14)	0.85				
Transient ischemic attack	5 (13)	3 (9)	0.56				
Diabetes mellitus	5 (13)	2 (6)	0.30				
Peripheral vascular disease	3 (8)	0 (0)	0.10				
Hyperlipidemia	5 (13)	6 (18)	0.60				
Dementia	5 (13)	9 (26)	0.15				
Smoking, current or ex	18 (47)	17 (50)	0.82				
Alcohol intake, units per week	0 (0-13)	2 (0-7)	0.97				
Medications							
BP-lowering							
None	17 (45)	20 (59)	0.42				
One	10 (26)	8 (24)					
Many	11 (29)	6 (18)					
Antiplatelet							
None	16 (42)	19 (56)	0.11				
One	22 (58)	13 (38)					
Many	0 (0)	2 (6)					
Anticoagulant							
None	32 (84)	30 (88)	0.62				
One	6 (16)	4 (12)					
Clinical assessment							
Systolic BP, mm Hg	179 (32)	163 (23)	0.023				
Diastolic BP, mm Hg	96 (23)	84 (15)	0.027				
GCS score	12 (9–14)	13 (11–14)	0.45				
ICH location*							
Lobar	12 (32)	28 (85)	<0.001				
Deep or infratentorial	26 (68)	5 (15)					

TABLE 1 Characteristics of patients with incident first-ever intracerebral hemorrhage, stratified by severity of cerebral amyloid angiopathy on research autopsy (LINCHPIN autopsy study, N = 72).

Data are number (%), mean (standard deviation), or median (interquartile range). ^Chi-squared test for categorical data; Kruskal–Wallis test for continuous data.

*One participant with moderate-severe cerebral amyloid angiopathy on research autopsy did not have diagnostic imaging available.



FIGURE 1

Systolic blood pressure during 10 years before incident first-ever intracerebral hemorrhage, stratified by severity of cerebral amyloid angiopathy on research autopsy: modeled using functional principle component analysis (LINCHPIN, N = 72). CAA, cerebral amyloid angiopathy; ICH, intracerebral hemorrhage.

TABLE 2 Patient-level long-term visit-to-visit systolic blood pressure variability during 10 years before incident first-ever intracerebral hemorrhage, stratified by severity of cerebral amyloid angiopathy on research autopsy (LINCHPIN autopsy study, *N* = 72).

Patient-level variable	Cerebral amyloi	P^{\wedge}					
	Absent-mild ($N = 38$)	Moderate-severe ($N = 34$)					
Total BP readings, median (IQR)	11 (5–23)	8 (2–16)	0.25				
Two or more BP readings ^{\$}	33 (87)	29 (85)	0.85				
Three or more BP readings#	30 (79)	25 (74)	0.59				
Systolic BP, mm Hg							
Mean, mean (SD)	145 (15)	143 (13)	0.59				
SBPV summary measure, mean (SD)							
SD (primary)	17 (6)	14 (8)	0.033				
Minimum	121 (18)	125 (20)	0.51				
Maximum	173 (25)	161 (20)	0.040				
Range	57 (25)	42 (25)	0.017				
CV	12 (4)	10 (5)	0.050				
RSD	17 (6)	14 (7)	0.032				

Data are number (%), mean (standard deviation), or median (interquartile range).

BP, blood pressure; SD, standard deviation; CV, coefficient of variation; RSD, residual standard deviation.

*From consensus histopathological rating for cerebral amyloid angiopathy.

^ Chi-squared test for categorical data; Kruskal-Wallis test for continuous data.

^{\$}Minimum number of readings required to calculate SD of systolic BP.

[#]Minimum number of readings required to calculate RSD of systolic BP.

CSVD (arteriolosclerosis; Banerjee et al., 2017; Wardlaw et al., 2019). In the systemic circulation, long-term visit-to-visit SBPV is associated with systemic arterial stiffness (Tedla et al., 2017), cardiovascular morbidity and mortality (Stevens et al., 2016), and the presence of CSVD on brain imaging (Tully et al., 2020). Thus, arterial stiffness may be a common mechanistic factor for the development of non-CAA CSVD and high long-term visit-to-visit SBPV. It is less clear, though, as to whether arterial stiffness

contributes to the pathogenesis of CAA, where there are changes in cerebral hemodynamics that can be attributed to amyloid- β deposition in the cerebrovascular vessel wall, and not the other way around (Banerjee et al., 2017). The finding that ICH patients with underlying moderate-severe CAA appear to have lower maximum and range of SBP during 10 years before onset of the ictus supports there being a smaller contribution to the pathogenesis of CAA from factors indicating vascular stiffness. This is an early step to TABLE 3 Association between patient-level long-term visit-to-visit systolic blood pressure variability during 10 years before incident first-ever intracerebral hemorrhage and moderate-severe cerebral amyloid angiopathy on research autopsy (LINCHPIN autopsy study, N = 72).

Systolic BP, mm Hg	Model 1		Model 2				
	aOR*	95% CI	Р	aOR*	95% CI	Р	
Mean	1.13	0.79-1.61	0.49	-	-	_	
SBPV summary measure							
SD (primary)	2.05	0.92-4.54	0.079	1.95	0.87-4.38	0.11	
Minimum	0.89	0.69-1.15	0.44	0.71	0.49-1.02	0.066	
Maximum	1.30	1.02-1.64	0.029	1.53	1.09-2.15	0.015	
Range	1.29	1.03-1.61	0.023	1.29	1.03-1.61	0.028	
CV	2.58	0.79-8.39	0.12	2.61	0.79-8.59	0.12	
RSD	2.30	0.90-5.87	0.080	2.14	0.78-5.85	0.14	

BP, blood pressure; CI, confidence interval; CV, coefficient of variation; aOR, adjusted odds ratio; RSD, residual standard deviation; SD, standard deviation.

*Per 10-point decrease in the systolic BP summary measure.

Model 1: binary logistic regression model adjusted for age and sex.

Model 2: binary logistic regression model adjusted for covariables in Model 1 and mean systolic BP.

understanding the role of BP in the pathogenesis of CAA, where few data were previously available (Banerjee et al., 2017).

The strengths of this study include the prospective, population-based design and completeness of demographic, clinical, radiological, BP, and histopathological data according to standard definitions. However, reliance on histopathological data limited the sample size for analysis, reducing both power to detect associations and an ability to fully adjust for multiple confounders. Further, meaningful analyses of the association between higher long-term visit-to-visit SBP levels and SBPV before ICH and the severity of non-CAA CVSD were hampered by the absence of histopathological ratings that adequately discriminate non-CAA CSVD severity in this cohort. Therefore, any conclusions about potential differences in SBP levels and SBPV according to CSVD subtype are limited by the reliance on the assumption that ICH in the context of absent-mild underlying CAA was likely to be related to non-CAA CVSD.

Further data are required to test the robustness of these preliminary findings about long-term visit-to-visit SBPV before ICH. To detect a true difference in the role of long-term visitto-visit SBPV in the pathogenesis of the two principal CSVD subtypes that cause ICH, larger patient and BP sample sizes are required. In the absence of large samples of histopathological data, external validation of the Edinburgh CT criteria for lobar ICH associated with CAA is a prerequisite for any future analyses that might aim to pool patient-level data from several rigorous population-based studies of ICH (Wolfe et al., 2002; Lovelock et al., 2007; Samarasekera et al., 2015a). Novel approaches to datalinkage may harness larger and more representative samples of BP data from various forms of BP tele-monitoring and wearable devices. The association of blood pressure control, including SBPV, with cognitive impairment associated with CAA also warrants further investigation.

Regarding non-CAA SVD, histopathological ratings of non-CAA CSVD that better represent the spectrum of this disease in ICH patients are needed to assess the association between longterm visit-to-visit SBPV before ICH and factors that indicate the presence of cerebral vessels at risk of rupture, such as lipohyalinosis and fibrinoid necrosis.

In conclusion, people with ICH who had moderate-severe CAA at autopsy had lower maximum and range of SBP before ICH compared to people with ICH with absent-mild CAA. These findings support there being differences in the role of BP control in the pathogenesis of the two main CSVD subtypes that cause ICH.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by Scotland A Research Ethics Committee. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

TM: Conceptualization, Formal analysis, Funding acquisition, Investigation, Writing—original draft, Writing—review and editing. RW: Data curation, Writing—review and editing. MR: Data curation, Writing—review and editing. NS: Conceptualization, Data curation, Investigation, Writing review and editing. JB: Formal analysis, Writing—review and editing. XW: Conceptualization, Formal analysis, Writing—review and editing. CH: Data curation, Writing—review and editing. JW: Data curation, Writing—review and editing. JW: Data curation, Writing—review and editing. AF: Data curation, Writing—review and editing. CS: Data curation, Writing—review and editing. CA: Supervision, Writing—review and editing. RA-S: Conceptualization, Data curation, Funding acquisition, Methodology, Supervision, Writing—review and editing. BM: Conceptualization, Methodology, Supervision, Writing—review and editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by a British Heart Foundation clinical research training fellowship grant (TM) and a UK Medical Research Council/Stroke Association clinical research training fellowship (NS).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships

References

Al-Shahi Salman, R., Labovitz, D. L., and Stapf, C. (2009). Spontaneous intracerebral haemorrhage. *BMJ* 339:b2586. doi: 10.1136/bmj.b2586

Arima, H., Tzourio, C., Anderson, C., Woodward, M., Bousser, M.-G., MacMahon, S., et al. (2010). Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the progress trial. *Stroke* 41, 394–396. doi: 10.1161/STROKEAHA.109.563932

Banerjee, G., Carare, R., Cordonnier, C., Greenberg, S. M., Schneider, J. A., Smith, E. E., et al. (2017). The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice. *J. Neurol. Neurosurg. Psychiatry* 88, 982–994. doi: 10.1136/jnnp-2016-314697

Biffi, A., Anderson, C. D., Battey, T. W. K., Ayres, A. M., Greenberg, S. M., Viswanathan, A., et al. (2015). Association between blood pressure control and risk of recurrent intracerebral hemorrhage. J. Am. Med. Assoc. 314, 904–912. doi: 10.1001/jama.2015.10082

Brott, T., Thalinger, K., and Hertzberg, V. (1986). Hypertension as a risk factor for spontaneous intracerebral hemorrhage. *Stroke* 17, 1078–1083. doi: 10.1161/01.STR.17.6.1078

Fischer, U., Cooney, M. T., Bull, L. M., Silver, L. E., Chalmers, J., Anderson, C. S., et al. (2014). Acute post-stroke blood pressure relative to premorbid levels in intracerebral haemorrhage versus major ischaemic stroke: a population-based study. *Lancet Neurol.* 13, 374–384. doi: 10.1016/S1474-4422(14)70031-6

Knudsen, K. A., Rosand, J., Karluk, D., and Greenberg, S. M. (2001). Clinical diagnosis of cerebral amyloid angiopathy: validation of the boston criteria. *Neurology* 56, 537–539. doi: 10.1212/WNL.56.4.537

Lovelock, C., Molyneux, A., and Rothwell, P. (2007). Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study. *Lancet Neurol.* 6, 487–493. doi: 10.1016/S1474-4422(07)70107-2

Ma, Y., Song, A., Viswanathan, A., Blacker, D., Vernooij, M. W., Hofman, A., et al. (2020). Blood pressure variability and cerebral small vessel disease: a systematic review and meta-analysis of population-based cohorts. *Stroke* 51, 82–89. doi: 10.1161/STROKEAHA.119.026739

O'Donnell, M. J., Chin, S. L., Rangarajan, S., Xavier, D., Liu, L., Zhang, H., et al. (2016). Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. *Lancet* 388, 761–775. doi: 10.1016/S0140-6736(16)30506-2

Rodrigues, M. A., Samarasekera, N., Lerpiniere, C., Humphreys, C., McCarron, M. O., White, P. M., et al. (2018). The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study. *Lancet Neurol.* 17, 232–240. doi: 10.1016/S1474-4422(18)30006-1

that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fstro.2023. 1278610/full#supplementary-material

Samarasekera, N., Fonville, A., Lerpiniere, C., Farrall, A. J., Wardlaw, J. M., White, P. M., et al. (2015a). Influence of intracerebral hemorrhage location on incidence, characteristics, and outcome: population-based study. *Stroke* 46, 361–368. doi: 10.1161/STROKEAHA.114.007953

Samarasekera, N., Lerpiniere, C., Fonville, A. F., Farrall, A. J., Wardlaw, J. M., White, P. M., et al. (2015b). Consent for brain tissue donation after intracerebral haemorrhage: a community-based study. *PLoS ONE.* 10, e0135043. doi: 10.1371/journal.pone.0135043

Samarasekera, N., Smith, C., and Salman, R. A. S. (2012). The association between cerebral amyloid angiopathy and intracerebral haemorrhage: systematic review and meta-analysis. *J. Neurol. Neurosurg. Psychiatry* 83, 275–281. doi: 10.1136/jnnp-2011-300371

Shen, M., Tan, H., Zhou, S., Smith, G. N., Walker, M. C., and Wen, S. W. (2017). Trajectory of blood pressure change during pregnancy and the role of pre-gravid blood pressure: a functional data analysis approach. *Sci. Rep.* 24:6227. doi: 10.1038/s41598-017-06606-0

Stata Press (2019). Stata Statistical Software: Release 16. StataCorp LLC.

Stevens, S. L., Wood, S., Koshiaris, C., Law, K., Glasziou, P., Stevens, R. J., et al. (2016). Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. *BMJ* 354:i4098. doi: 10.1136/bmj. i4098

Tedla, Y. G., Yano, Y., Carnethon, M., and Greenland, P. (2017). Association between long-term blood pressure variability and 10-year progression in arterial stiffness. *Hypertension* 69, 118–127. doi: 10.1161/HYPERTENSIONAHA.116.08427

The Mathworks Inc. (2019). MATLAB (R2019a). MathWorks Inc.

Tully, P. J., Yano, Y., Launer, L. J., Kario, K., Nagai, M., Mooijaart, S. P., et al. (2020). Association between blood pressure variability and cerebral small-vessel disease: a systematic review and meta-analysis. *J. Am. Heart Assoc.* 9:e013841. doi: 10.1161/JAHA.119.013841

Wardlaw, J. M., Smith, C., and Dichgans, M. (2019). Small vessel disease: mechanisms and clinical implications. *Lancet Neurol.* 18, 684–696. doi: 10.1016/S1474-4422(19)30079-1

Weinberger, J. (2001). Randomised trial of a perindopril-based bloodpressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. *Lancet* 358, 1033–1041. doi: 10.1016/S0140-6736(01) 06178-5

Wolfe, C. D. A., Rudd, A. G., Howard, R., Coshall, C., Stewart, J., Lawrence, E., et al. (2002). Incidence and case fatality rates of stroke subtypes in a multiethnic population: the South London stroke register. *J. Neurol. Neurosurg. Psychiatry* 72, 211–216 doi: 10.1136/jnnp.72.2.211